Trimpex

Shigellosis, Nocardiosis, Brucellosis + 16 more
Treatment
17 FDA approvals
18 Active Studies for Trimpex

What is Trimpex

TrimethoprimThe Generic name of this drug
Treatment SummaryTrimethoprim is an antibiotic medicine used to treat bacterial infections. It works by blocking the formation of an important enzyme that helps the bacteria survive. It is usually taken with another antibiotic, sulfamethoxazole, for maximum effectiveness. It is related to pyrimethamine, another antibiotic used to treat malaria.
Septra DSis the brand name
Trimpex Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Septra DS
Trimethoprim
1973
343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including susceptible Enteritis infectious caused by Shigella sonnei and Urinary tract infection .
susceptible Enteritis infectious caused by Shigella sonnei
Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole
Urinary tract infection
Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole
Nocardiosis
Used to treat Nocardiosis in combination with Sulfamethoxazole
Fluid replacement therapy
Used to treat Fluid replacement therapy in combination with Sulfamethoxazole
Cholera
Used to treat susceptible Cholera in combination with Sulfamethoxazole
Pneumonia, Pneumocystis
Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole
Genus Pneumocystis
Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole
Otitis Media
Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole
Brucellosis
Used to treat Brucellosis in combination with Rifampicin
Electrolyte replacement
Used to treat Electrolyte replacement in combination with Sulfamethoxazole
Pneumocystis Jirovecii Pneumonia
Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole
Shigellosis
Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole
Bronchitis
Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole
Diarrhea
Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole
susceptible Enteritis infectious caused by Shigella flexneri
Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole
Brucellosis
Used to treat Brucellosis in combination with Rifampicin
Immunocompromised
Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Trimpex Affects PatientsTrimethoprim works by stopping bacteria from making the proteins and nucleic acids they need to survive. It is effective against some types of gram-negative bacteria and certain types of Staphylococcus. Bacteria can become resistant to trimethoprim if they make changes to their cell wall, produce more of an enzyme (dihydrofolate reductase) or make an enzyme that is resistant to trimethoprim. Taking trimethoprim can sometimes lead to blood disorders such as thrombocytopenia and leukopenia. It is important to watch for signs of these disorders such
How Trimpex works in the bodyTrimethoprim is a medication that works to kill bacteria. It does this by stopping bacteria from making a type of acid, called tetrahydrofolic acid, which they need to survive. Trimethoprim works better on bacteria than on human cells, so it only affects bacteria, not people. Trimethoprim can be taken alone or with another medication, sulfamethoxazole, which works in a similar way. Together, these two medications block two steps in the process of bacterial growth, making them more effective at killing bacteria.

When to interrupt dosage

The suggested dose of Trimpex is contingent upon the diagnosed condition, including Urinary tract infection, Immunocompromised and Pneumocystis Jirovecii Pneumonia. The amount additionally depends on the method of delivery (e.g. Tablet - Oral or Tablet) outlined in the table below.
Condition
Dosage
Administration
Conjunctivitis, Bacterial
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Pneumonia, Pneumocystis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Brucellosis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Immunocompromised
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Nocardiosis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Urinary tract infection
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
bacterial blepharitis caused by susceptible bacteria
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Urinary tract infection
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Diarrhea
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Shigellosis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Electrolyte replacement
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Fluid replacement therapy
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Genus Pneumocystis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Bacterial conjunctivitis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Bronchitis
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
susceptible Enteritis infectious caused by Shigella flexneri
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
susceptible Enteritis infectious caused by Shigella sonnei
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Otitis Media
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic
Cholera
, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL
Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Liquid - Intravenous, Liquid, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Injection, Solution / drops, Liquid - Ophthalmic

Warnings

Trimpex has eight contraindications and should not be administered concurrently with any of the disorders listed in the following table.Trimpex Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Trimethoprim may interact with Pulse Frequency
Purpura, Thrombocytopenic, Idiopathic
Do Not Combine
hepatic damage
Do Not Combine
Megaloblastic anemia caused by Folate deficiency
Do Not Combine
unable to monitor renal function
Do Not Combine
Disease
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Trimethoprim may interact with Pulse Frequency
There are 20 known major drug interactions with Trimpex.
Common Trimpex Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Trimethoprim.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Trimethoprim.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.
Cisplatin
Major
The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.
Clofarabine
Major
The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.
Trimpex Toxicity & Overdose RiskThe toxic dose of trimethoprim for mice and rats is 2764 mg/kg and greater than 5300 mg/kg respectively. Signs of overdose may appear if the patient has taken more than 1 gram of trimethoprim, including nausea, vomiting, dizziness, headaches, confusion, and reduced bone marrow function. Treatment should include supportive care and potentially stomach pumping, as well as increasing acidity in the urine to help remove the drug from the body. Dialysis is only partially effective in removing trimethoprim from the bloodstream.

Trimpex Novel Uses: Which Conditions Have a Clinical Trial Featuring Trimpex?

Currently, 8 clinical trials are being conducted to assess the effectiveness of Trimpex in treating Shigella flexneri-induced Enteritis Infectious, Bacterial-induced Blepharoconjunctivitis and Diarrhea.
Condition
Clinical Trials
Trial Phases
Urinary tract infection
0 Actively Recruiting
Bacterial conjunctivitis
0 Actively Recruiting
Bronchitis
0 Actively Recruiting
Nocardiosis
0 Actively Recruiting
Shigellosis
0 Actively Recruiting
Brucellosis
0 Actively Recruiting
bacterial blepharitis caused by susceptible bacteria
0 Actively Recruiting
Immunocompromised
3 Actively Recruiting
Not Applicable, Phase 1
Otitis Media
0 Actively Recruiting
Genus Pneumocystis
0 Actively Recruiting
Conjunctivitis, Bacterial
0 Actively Recruiting
Fluid replacement therapy
0 Actively Recruiting
Cholera
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
susceptible Enteritis infectious caused by Shigella sonnei
0 Actively Recruiting
Pneumonia, Pneumocystis
1 Actively Recruiting
Phase 3
susceptible Enteritis infectious caused by Shigella flexneri
0 Actively Recruiting
Electrolyte replacement
0 Actively Recruiting
Diarrhea
14 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1

Patient Q&A Section about trimpex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is trimethoprim prescribed for?

"Trimethoprim is a medication used to treat and prevent urinary tract infections. It can also be used to treat other types of infections such as chest infections and acne, though this is less common. Trimethoprim requires a prescription from a doctor."

Answered by AI

What are the side effects of taking trimethoprim?

"The following are symptoms of oxygen deprivation: black, tarry stools; blood in urine or stools; bluish fingernails, lips, or skin; changes in facial skin color; difficult breathing or shortness of breath; fever with or without chills; general feeling of discomfort or illness; neck stiffness."

Answered by AI

What is Proloprim used for?

"It is used to treat bacterial infections."

Answered by AI

What is Trimpex used for?

"Trimethoprim is used to treat bacterial infections. It stops the growth of the bacteria. This antibiotic only works for bacterial infections and won't work for viral infections like the common cold or the flu."

Answered by AI

Clinical Trials for Trimpex

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.
Phase < 1
Waitlist Available
Stanford Digestive Health Clinic (+1 Sites)Sean P Spencer, MD, PhD
Have you considered Trimpex clinical trials? We made a collection of clinical trials featuring Trimpex, we think they might fit your search criteria.Go to Trials
Have you considered Trimpex clinical trials? We made a collection of clinical trials featuring Trimpex, we think they might fit your search criteria.Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.
Phase 3
Waitlist Available
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)Emily G McDonald, MD MSc
Image of Temple University in Philadelphia, United States.

UV Water Treatment for Gastroenteritis in Children

6 - 59
All Sexes
Philadelphia, PA
Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.
Recruiting
Paid Trial
Temple UniversityHeather M Murphy, PhD
Have you considered Trimpex clinical trials? We made a collection of clinical trials featuring Trimpex, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security